View Document Preview and Link Document Date: 2008-09-17 23:34:08 Open Document File Size: 88,64 KB Share Result on Facebook
City Tokyo / Deerfield / / Company Astellas Astellas Pharma US Inc. / Maribeth Landwehr Astellas US LLC / Astellas Pharma US Inc. / Toronto Stock Exchange / Astellas Pharma Inc. / Cardiome Pharma Corp. / / Continent North America / / Country United States / Canada / Mexico / / / Event Business Partnership / FDA Phase / / IndustryTerm biotechnology / manufacturing / pharmaceutical products / pharmaceutical / / MedicalCondition atrial fibrillation / disorders / / MedicalTreatment cardioversion / / Organization U.S. Food and Drug Administration / FDA / Securities and Exchange Commission / / Person William E. Fitzsimmons / Bob Rieder / Peter K. Hofman / / / Position Senior Vice President / Research & Development / Director / global category leader / Private / Chief Executive Officer and Chairman / / Product KYNAPIDTM Vancouver / KYNAPID™ (vernakalant hydrochloride) / / ProvinceOrState Illinois / / Technology biotechnology / Anti-Infectives / drug development / / URL www.sec.gov / www.cardiome.com / www.sedar.com / www.astellas.com/us / / SocialTag 
FOR IMMEDIATE RELEASE NASDAQ: CRME TSX: COM CARDIOME AND ASTELLAS ANNOUNCE RECEIPT OF FDA APPROVABLE LETTER FOR KYNAPIDTM